Abstracts tagged "genomics and giant cell arteritis"

Abstract Number: 872 • 2016 ACR/ARHP Annual Meeting
New Insights into the Pathogenesis of Giant Cell Arteritis through a Genome-Wide Association Study
Francisco David Carmona¹, Augusto Vaglio², Sarah Mackie³, José Hernández-Rodríguez⁴, Paul A. Monach⁵, Santos Castañeda⁶, Roser Solans⁷, Inmaculada C. Morado⁸, Francisco Javier Narváez⁹, Marc Ramentol-Sintas¹⁰, Colin T. Pease¹¹, Bhaskar Dasgupta¹², Richard Watts¹³, Nader A. Khalidi¹⁴, Carol A. Langford¹⁵, Steven R. Ytterberg¹⁶, Luigi Boiardi¹⁷, Lorenzo Beretta¹⁸, Marcello Govoni¹⁹, Giacomo Emmi²⁰, Francesco Bonatti²¹, Marco A. Cimmino²², Torsten Witte²³, Thomas Neumann²⁴, Julia Holle²⁵, Verena Schönau²⁶, Laurent Sailler²⁷, Thomas Papo²⁸, Julien Haroche²⁹, Alfred Mahr³⁰, Luc Mouthon³¹, Øyvind Molberg³², Andreas P Diamantopoulos³³, Alexandre E. Voskuyl³⁴, Elisabeth Brouwer³⁵, Thomas Daikeler³⁶, Christoph Berger³⁷, Eamonn S. Molloy³⁸, Lorraine O'Neill³⁹, Daniel Blockmans⁴⁰, Benedicte A. Lie⁴¹, Paul Mclaren⁴², Timothy J. Vyse⁴³, Cisca Wijmenga⁴⁴, Yannick Allanore⁴⁵, Bobby P.C. Koeleman⁴⁶, Jennifer H. Barrett⁴⁷, Maria C. Cid⁴⁸, Carlo Salvarani⁴⁹, Peter A. Merkel⁵⁰, Ann W. Morgan⁵¹, Miguel Angel González-Gay⁵², Javier Martín¹ and Spanish GCA Group, UKGCA Consortium, and Vasculitis Clinical Research Consortium, ¹Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, PTS-Granada, Granada, Spain, ²Nephrology, University Hospital of Parma, Parma, Italy, ³NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, University of Leeds, Leeds, United Kingdom, ⁴Department of Autoimmune Diseases, Hospital Clínic University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ⁵Rheumatology, Boston University School of Medicine, Boston, MA, ⁶Rheumatology, Hospital de la Princesa, IIS-IP, Madrid, Spain, ⁷Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Hospital Vall d'Hebron, Autonomous University of Barcelona, Spain, Barcelona, Spain, ⁸Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ⁹Rheumatology, Hospital Universitario de Bellvitge-IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain, ¹⁰Internal Medicine, Hospital Vall d’Hebron, Autonomous University of Barcelona, Barcelona, Spain, ¹¹Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ¹²Rheumatology, Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, ¹³Rheumatology, Ipswich Hospital NHS Trust, Ipswich, United Kingdom, ¹⁴Rheumatology, McMaster University, Hamilton, ON, Canada, ¹⁵Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ¹⁶Rheumatology, Mayo Clinic, Rochester, MN, ¹⁷Rheumatology Unit, Department of Internal Medicine, Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy, ¹⁸Scleroderma Unit, Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ¹⁹Medical Sciences, UOC of Rheumatology, University Hospital S. Anna, Cona Ferrara, Italy, ²⁰Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ²¹Clinical and Experimental Medicine, Medical Genetics Unit, University of Parma, Parma, Italy, ²²Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, ²³Department of Clinical Immunology and Rheumatology, Hannover Medical School, Hannover, Germany, ²⁴Internal Medicine III, Jena University Hospital, Jena, Germany, ²⁵Vasculitis Clinic, Klinikum Bad Bramstedt & University Hospital of Schleswig Holstein, Bad Bramstedt, Germany, ²⁶Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany, ²⁷Internal Medicine, Internal Medicine department, Toulouse University Hospital, Toulouse, France, ²⁸Internal Medicine, Hôpital Bichat, Université Paris-Diderot, Paris, France, ²⁹Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ³⁰Internal Medicine, Hospital Saint-Louis, Paris, France, ³¹Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ³²Rheumatology, Oslo University Hospital, Oslo, Norway, ³³Rheumatology, Haugesund Sanitetsforenings Revmatismesykehus, Haugesund, Norway, ³⁴Rheumatology, Amsterdam Rheumatology and immunology Center, Location VU University Medical Center, Amsterdam, Netherlands, ³⁵Rheumatology and Clinical Immunology, University of Groningen and University Medical Center Groningen, Groningen, Netherlands, ³⁶Rheumatology, University Hospital Basel, Basel, Switzerland, ³⁷Internal medicine, University hospital Basel, basel, Switzerland, ³⁸Rheumatology, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, St Vincent's University Hospital, Dublin, Ireland, ³⁹Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ⁴⁰General Internal Medicine, University Hospitals Gasthuisberg, Leuven, Belgium, ⁴¹Department of Medical Genetics, University of Oslo and Oslo University Hospital, Oslo, Norway, ⁴²Swiss Institute of Bioinformatics, Lausanne, Switzerland, ⁴³Division of Immunology, Infection and Inflammatory Disease, King’s College London, London, United Kingdom, ⁴⁴Genetics, University Medical Hospital Groningen, University of Groningen, Groningen, Netherlands, ⁴⁵Rheumatology, Paris Descartes University, Paris, France, ⁴⁶Medical Genetics, University Medical Centre Utrecht, Utrecht, Netherlands, ⁴⁷NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁴⁸Autoimmune and Systemic Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ⁴⁹Rheumatology, Azienda Ospedaliera ASMN, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy, ⁵⁰Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁵¹Section of Musculoskeletal Disease, NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom, ⁵²Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain
Background/Purpose: Giant cell arteritis (GCA) is an immune-mediated polygenic disease characterized by inflammatory lesions in medium- and large-sized arteries. The aim of the present study…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].